Is There a Real Substitute for Mounjaro for Weight Loss?

What makes Mounjaro different from other weight-loss medicines — and why does it matter when choosing a substitute?

Tirzepatide activates two gut-hormone receptors simultaneously: GLP-1 and GIP. GLP-1 agonism slows gastric emptying, reduces appetite, and improves insulin response. GIP agonism adds a separate layer of metabolic effect. No other UK-licensed weight-loss medicine does both. Wegovy (semaglutide) targets GLP-1 only. Orlistat targets neither, it inhibits the enzyme that digests fat in the gut, blocking absorption of roughly a third of the fat you eat. These aren't subtle differences in dosing; they're fundamentally different approaches to the same problem.

Why does this matter when you're looking for a substitute? Because the results vary. In the SURMOUNT-5 trial (a direct head-to-head comparison published in the New England Journal of Medicine) tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks in adults with obesity who did not have type 2 diabetes. That doesn't make semaglutide ineffective; the STEP 1 trial showed roughly 15% average body-weight reduction over 68 weeks at the 2.4mg maintenance dose, which is clinically significant for most people. It just means the mechanisms, and the numbers, differ. If you want to explore what the evidence says about whether a substitute for Mounjaro can genuinely replicate its results, that question is worth unpacking before committing to a switch. Understanding that gap is the starting point for any honest conversation about substitutes.

Eligibility differs too. You can read more about who qualifies for Mounjaro under its UK licence, those criteria don't automatically transfer to other medicines.

What are the closest licensed substitutes if Mounjaro isn't right for you?

Wegovy (the semaglutide injection) is the most studied like-for-like alternative for weight management in the UK. It's a once-weekly subcutaneous injection, and most adults follow the same titration pattern (starting low and working up over several months) that tirzepatide users will recognise. On 14 April 2026 the MHRA approved a dedicated single-dose 7.2mg Wegovy pen, and trial data at that higher dose reported around 20.7% average weight loss over 72 weeks, closing the gap with tirzepatide's headline figures meaningfully. The NHS medicines page for semaglutide covers the side-effect profile and how the injection works in plain language.

The oral Wegovy tablet is newer still. The MHRA approved it on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management. It uses the same semaglutide molecule but in a once-daily tablet, taken on an empty stomach first thing in the morning. Phase 3 trial data (OASIS 4) showed around 13.6% average weight loss versus roughly 2.4% on placebo over 64 weeks, or approximately 17% among participants who stayed fully adherent. For anyone who finds injections a barrier, this is a clinically meaningful option. Storage is room-temperature, which some people find easier, especially when travelling.

For a side-by-side look at how these two medicines compare on mechanism and results, the tirzepatide vs Mounjaro comparison page walks through the evidence in more detail. If you're exploring alternatives because of cost rather than clinical reasons, it's worth reading the cost context page first, the price picture has shifted considerably since Eli Lilly raised list prices in September 2025.

What about orlistat, is it a realistic option as a Mounjaro substitute?

Orlistat is the only non-hormonal licensed weight-management medicine in the UK, and it works by a completely different route: it blocks pancreatic lipase, the enzyme that breaks down dietary fat, so roughly a third of the fat in each meal passes through unabsorbed. There's no effect on appetite hormones, no gastric emptying slowdown, and no impact on blood sugar. The result is meaningful weight loss for many people, but the profile of results (and the side-effect pattern) is quite different from GLP-1 or dual-agonist medicines.

In practical terms, orlistat works best alongside a genuinely low-fat diet; if fat intake stays high, the gastrointestinal side effects (loose stools, oily discharge) become significant. It's available as a prescription medicine (120mg capsules, three times daily with meals) and in a lower-strength over-the-counter version (60mg) for adults with a BMI of 28 or above. NICE guidance on obesity management covers where orlistat fits in the clinical pathway. It's rarely described as a substitute for tirzepatide in the clinical sense, but our page looking at what actually qualifies as a substitute for Mounjaro, and how each option compares, covers orlistat alongside the injectable and oral alternatives so you can weigh them up properly. For some people (particularly those for whom GLP-1 side effects are problematic, or whose BMI or health profile doesn't meet the threshold for injectable medicines) it remains a valid option worth raising with a prescriber.

The weight management treatment overview sets out the full range of options available in the UK, including how licensed medicines sit alongside dietary and behavioural approaches.

How do prescribers actually decide which medicine to use?

The short answer: it depends on your BMI, your health history, your other medicines, and (practically) what you can access. A prescriber reviewing your consultation will consider whether you meet the licensed criteria for each medicine, whether any contraindications apply, how you feel about injections versus tablets, and whether a previous GLP-1 trial has already given them information about how you respond. Transfer patients coming from another medicine need to provide evidence of their current treatment and dose before a prescriber can advise on switching.

It's also worth being realistic about timing. If Mounjaro has become unavailable at your current dose mid-course (which can happen, and sometimes lines up with the worst possible moments (a bank holiday, just before you go away, payday still a week off)) a prescriber will want to know how long you've been on your current regimen before recommending a switch rather than a temporary hold. Switching GLP-1 medicines mid-titration isn't automatic; the starting dose on a new medicine may differ from where you've reached on the original, and the prescriber needs to judge that individually.

Questions about your specific situation are worth putting to a clinician rather than resolving from a comparison page. If you'd like to speak to our prescribers, a free consultation with a GPhC-registered Independent Prescriber is the starting point, your consultation is reviewed by a real clinician the same day, and a named person makes the call, not software. Our clinical approach is set out on the about page if you'd like to read more before starting.